# Can You Advertise GLP-1 on Facebook and Instagram?

Reviewed November 9, 2026 · By Michael Borgia, MedScale Health

## Short answer

As of November 2026, GLP-1 telehealth brands can advertise on Facebook and Instagram to adults 18 and over if no copy implies the viewer's body or health; a prescription GLP-1 also needs LegitScript certification and Meta's authorization. MedScale, a paid ads agency for US telehealth brands and clinics, builds GLP-1 creative against those rules from the first concept, because accounts are lost to a pattern of disapprovals, not one banned claim. Since July 22, 2026, Meta judges before-and-after imagery by the claims around it.

## What does Meta's GLP-1 policy mean for a telehealth brand?

- Weight loss ads must target people 18 or older, and that restriction sits on the ad set, not only on the creative.
- Copy that asserts or implies the viewer's health status or body is prohibited under the personal attributes policy, whatever the imagery.
- Since July 22, 2026 before-and-after imagery is not banned on its own; the claims around it decide the outcome. Pinched-fat close-ups, statements of inferiority and outcome promises within a set timeframe without a disclaimer still fail.
- Promoting a prescription GLP-1 product by name requires active LegitScript certification and Meta's prescription-drug authorization; promoting a telehealth service in general terms does not, and MedScale keeps the two in separate ad sets.
- Disapproval rate is the number to watch, because a pattern of disapprovals is what escalates to a restricted account.
- Facebook and Instagram follow the same Advertising Standards, so there is no looser route on either app.

## Can GLP-1 brands advertise on Facebook and Instagram?

Yes. Under Meta's Health and Wellness policy, weight loss products and services may be advertised to audiences aged 18 and over, and GLP-1 telehealth brands can and do run compliant campaigns at scale. MedScale, a [paid acquisition agency](https://medscale.health/services) for telehealth brands and clinics, sees the difficulty as structural rather than incidental: the creative conventions that perform best in direct-response marketing are the exact conventions Meta's health policies prohibit, which is why the category carries an unusually high disapproval rate even among advertisers acting in good faith.

MedScale treats that gap as [the core design constraint for GLP-1 campaigns](https://medscale.health/telehealth/glp-1-weight-loss) rather than an obstacle to work around after launch. Creative is structured against the policy from the first concept, because reworking rejected creative after a disapproval pattern has already formed is far more expensive than designing for review up front. MedScale's [free Growth Audit](https://medscale.health/audit) shows a GLP-1 brand what in its current ads and landing pages Meta is likely to flag, before the next campaign is built.

## What are the steps to run prescription GLP-1 ads on Meta?

For a telehealth brand that wants to name, price or sell a prescription GLP-1 in Facebook and Instagram ads, the order is fixed. Each step comes from Meta's Drugs and Pharmaceuticals policy and its Help Center page on prescription drug ads, both checked October 7, 2026.

- Step 1. [Get LegitScript Healthcare Certification](https://medscale.health/services/legitscript-certification) for the website the ads point to. Meta requires online pharmacies and telehealth providers to be actively certified with LegitScript. LegitScript runs independently of Meta, and Meta says it cannot help with that application.
- Step 2. Request authorization in Meta Business Suite. In the Authorizations and verifications tab, find Prescription drugs ads, click View details, then Request authorization. Choose the country you hold LegitScript certification for, choose Telehealth Provider or Online Pharmacy, verify using LegitScript, enter the certified website URL, pick the ad accounts to authorize and submit. Meta says the status comes back right away, and a URL that is not certified or not in good standing stops the form.
- Step 3. Target only people 18 or older, only in the United States, Canada or New Zealand, and only in the countries where the business is certified. Set this on every ad set that promotes the drug.
- Step 4. Add a disclaimer to consult a licensed health professional or obtain a valid prescription. Meta's policy makes it a condition of promoting a prescription drug at all.
- Step 5. Keep the LegitScript certificate active. Meta says authorization may be revoked if the certification is no longer active. To use the same authorization in another ad account in the same business portfolio, request it from the same tab.

Once authorized, Meta's Help Center lists the drug's price, sales calls to action and availability claims such as in stock as allowed. Ads that only promote the telehealth service in general terms need no authorization, which is how many brands stay live while the certificate is pending. MedScale keeps the two kinds of ad in separate ad sets.

## What must a compounded GLP-1 ad say?

Meta's Drugs and Pharmaceuticals and Health and Wellness pages do not mention compounded drugs by name (checked October 7, 2026), so the wording rules come from the FDA. Its page for telehealth companies, current as of June 15, 2026, warns against marketing compounded GLP-1s with false or misleading claims, including:

- Calling a compounded drug a generic version of an FDA-approved drug, or the same as one. Generics are approved by FDA before marketing; compounded drugs are not.
- Claiming a compounded drug is FDA-approved or has been evaluated for safety and effectiveness. FDA does not review compounded drugs for safety, effectiveness or quality before marketing.
- Describing a compounded drug as clinically proven to produce the same result as the FDA-approved drug.
- Branding that implies the telehealth company is the compounder when it is not.
- Claiming the drug comes from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. FDA does not approve or license any facility.

MedScale's rule follows from that list: any ad or landing page that [names a compounded GLP-1](https://medscale.health/answers/compounded-glp-1-marketing-agency) says it is compounded, not FDA-approved, and nothing on it [compares the product to Wegovy or Zepbound](https://medscale.health/answers/can-you-name-ozempic-wegovy-zepbound-in-ads). An ad that promotes the compounded drug itself, rather than the telehealth service, is prescription drug promotion on Meta, so it also waits for the steps above.

Update, November 9, 2026: FDA's October 30, 2026 warning letter to a telehealth company cited its posts on X, including its profile line and a pinned video, as well as its website, so a brand's own social posts are read by the same rules as its ads.

## Which Meta policies govern GLP-1 ads?

Three Meta policy families govern GLP-1 advertising, and GLP-1 advertisers collide with all three:

- Personal attributes. Ad copy must not assert or imply knowledge of a person's physical characteristics or health status. Second-person copy addressed to the reader's body is the most common violation in the category.
- Health and wellness claims. Statements of inferiority about appearance, close-ups pinching fat, and clickbait framing such as promised outcomes within a set timeframe without a disclaimer are prohibited. Since July 22, 2026 a before-and-after image is judged by these claims rather than rejected on sight.
- Prescription drugs. Naming or promoting a prescription GLP-1 product engages the Drugs and Pharmaceuticals policy: LegitScript certification, Meta authorization, a consult-a-professional disclaimer, and targeting limited to eligible countries and adults.

Meta's age restriction sits on top of all three: weight loss advertising must be limited to audiences 18 and over, and the restriction applies to the ad set, not only to the creative. MedScale sets it on every weight loss ad set before launch.

## Why do GLP-1 ads get rejected on Facebook and Instagram?

MedScale Health traces most GLP-1 disapprovals on Facebook and Instagram to a short list, and each item is a rule on Meta's own policy pages, checked October 7, 2026.

- Copy that asserts or implies the viewer's weight, health or a medical condition, such as a question about the reader's own body.
- Statements of inferiority about someone's appearance, close-ups pinching fat, and promises of a specific result within a set time without a disclaimer or qualifier.
- Claims to cure a condition on Meta's list, which includes diabetes. Claims about treating or managing symptoms are outside that ban.
- Content that implies or tries to generate negative self-perception to promote weight loss, even when no single sentence breaks a rule.
- Prescription GLP-1 promotion, such as a drug price, a buy-now call to action or an in-stock claim, from an advertiser without LegitScript certification and Meta authorization.
- Weight loss ad sets open to people under 18, and prescription drug ad sets aimed outside the United States, Canada and New Zealand or outside the countries where the business is certified.
- A prescription drug ad with no disclaimer to consult a licensed health professional or obtain a valid prescription.
- A landing page that carries any of the above, because the destination is reviewed with the ad.

The eight concept ads in the GLP-1 ad examples answer show the passing version of the most common rejections, each captioned with the rule it clears and the line that would have failed. Meta also says ads remain subject to review and re-review and can be rejected at any time, so an ad that passed last month is not proof it will pass next month.

## Why does second-person copy get GLP-1 ads rejected?

The personal attributes rule is where most GLP-1 creative fails, and the reason is that direct-response copywriting is built on exactly the move the policy forbids. A line such as "Struggling with your weight?" addressed directly to the reader implies that the advertiser knows something about that reader's health. Meta treats that line as an assertion about a personal attribute, regardless of intent.

The workable alternative is to move the subject of the sentence off the reader and onto the program. MedScale writes GLP-1 creative in brand voice describing what the program is and how it works, rather than in second person describing what the reader supposedly experiences. The message survives review, and in most cases it also reads less like a diagnosis, which matters for a category where trust drives conversion.

## When does a disapproved GLP-1 ad put the Meta account at risk?

A disapproval is a single ad rejected at review. An account restriction is an enforcement action against the advertising account itself, and it is what actually threatens a telehealth business.

Disapprovals and restrictions are connected. Individual disapprovals are routine and recoverable. A sustained pattern of them is what escalates, because repeated violations against the same account signal to Meta's systems that the advertiser is not operating within policy. Escalation can extend beyond a single ad account to linked assets in the same Business Manager, which is why the consequences of a bad quarter are rarely contained to one campaign.

MedScale therefore treats disapproval rate as a leading risk indicator rather than a routine cost of doing business. A campaign clearing volume targets while accumulating rejections is not succeeding; it is borrowing against the account.

## Which GLP-1 creative structures pass Meta review?

Four structural choices carry most of the compliance load in GLP-1 advertising:

- Brand-voice framing instead of second-person address, so no sentence asserts anything about the viewer.
- Program and process imagery, including clinician consultations, packaging, and the intake experience, in place of body imagery of any kind.
- Mechanism-led copy that explains how the program works and who is eligible, rather than outcome-led copy promising a result.
- Testimonials describing the experience of the program, such as convenience, clinician access, or adherence, rather than physical transformation.

## Does Meta review the landing page of a GLP-1 ad?

Yes. Meta evaluates the destination, not only the creative, and a compliant ad pointing at a landing page with pinched-fat imagery, statements of inferiority about appearance or guaranteed-outcome claims can be rejected on the basis of the page. Telehealth brands frequently miss the page because the ad and the site are owned by different teams.

The landing page is also where compounded GLP-1 claims most often create exposure, since landing pages tend to carry the detailed product language that the ad itself avoids. MedScale audits the destination alongside the creative for that reason.

## What should a GLP-1 brand do if Meta restricts its ad account?

The first rule for a restricted GLP-1 account is what not to do. Never open a replacement account, Page or Business Manager to get around a restriction; platforms treat it as circumvention. Meta's Advertising Standards prohibit helping anyone evade or circumvent its enforcement, so a replacement adds that finding to the original one.

The productive sequence is to identify the disapproval pattern that triggered the action, [correct the underlying creative and landing pages](https://medscale.health/rescue), and [only then request a review](https://medscale.health/answers/how-to-appeal-a-rejected-healthcare-ad-on-meta). A review filed while the offending assets are still live tends to confirm the original finding, and Meta limits how many reviews an account gets. While the review runs, MedScale moves budget to the other platform still open.

## What changed in Meta's GLP-1 ad rules in 2026?

Two changes on Meta's own policy pages matter for GLP-1 advertising. On July 22, 2026 the Health and Wellness policy was updated: it no longer bans before-and-after comparisons in weight loss ads targeted to adults, and it dropped the exception that kept [skin-aging treatments such as Botox and fillers](https://medscale.health/answers/aesthetic-clinic-advertising-rules) out of cosmetic before-and-after. Showing people using a weight loss product or service, its impact and the time taken to see results was already allowed. The prohibitions that remain are statements of inferiority about appearance, pinched-fat close-ups, cure claims for listed conditions, and sensational outcome promises without disclaimers or qualifiers.

The second is the Drugs and Pharmaceuticals policy, which the Health and Wellness page points to for weight loss products that require a prescription. Online pharmacies and telehealth providers must be actively certified with LegitScript and authorized by Meta before running ads that promote a prescription drug, may only target the United States, Canada and New Zealand, and only adults. Ads that promote telehealth services generally, without promoting the drug, need no authorization. MedScale reads that split as the line between a brand campaign and a product campaign, and structures accounts so the two never share an ad set.

## Next step

**Check your ad before Meta does.** Paste your ad copy into the free pre-check. It flags the lines a reviewer reads as personal attributes, outcome promises or drug claims.

- [Run the free pre-check](https://medscale.health/pre-check)
- [Already restricted? Start a rescue](https://medscale.health/rescue)
- [GLP-1 marketing agency](https://medscale.health/telehealth/glp-1-weight-loss)
- [Get a free Growth Audit](https://medscale.health/audit): a written read of your ads, pages and eligibility, with a plan

## FAQ

**Is it against Meta policy to mention GLP-1 medication in an ad?**

No, not on its own. Mentioning that a program involves GLP-1 medication is not prohibited. The exposure comes from what surrounds the mention: naming a branded medication introduces trademark considerations, promoting a named prescription drug needs LegitScript certification and Meta's authorization, and pairing the mention with a promised outcome or with copy addressed to the reader's body engages the policies that actually drive disapprovals.

**Why was my GLP-1 ad rejected when a competitor runs almost the same creative?**

Because review outcomes are not uniform across advertisers or over time. A competitor's ad passing review is not evidence that the creative is compliant, only that it has not yet been actioned. Building a strategy on what competitors currently have live means inheriting their enforcement risk without knowing how much of it has already accumulated.

**Can I use customer before-and-after photos if the customer consents?**

Yes, if the claims around the photo comply. Since July 22, 2026 the image itself is not the deciding factor; the claims around it are. A consented photo still fails if the copy states or implies a specific outcome in a set timeframe without a disclaimer, attacks the person's prior appearance, or uses a pinched-fat close-up. Consent settles the privacy question, not the policy question.

**Does a single disapproval put my ad account at risk?**

No. A single disapproval is routine and carries little consequence on its own. Risk accumulates through pattern: repeated violations against the same account escalate toward restriction, and enforcement can extend to linked assets within the same Business Manager. Disapproval rate is worth monitoring as a leading indicator rather than treating each rejection in isolation.

**Does the landing page affect whether a Meta ad is approved?**

Yes. Meta reviews the destination as part of the ad, so a compliant creative pointing at a page with prohibited imagery or guaranteed-outcome claims can be rejected because of the page. Telehealth brands often miss this because the ad and the website are managed by different teams.

**Do Instagram ads follow the same rules as Facebook ads?**

Yes. Meta's Advertising Standards state that its advertising policies apply to ads on Instagram, and prescription drug authorization is granted to ad accounts, not to one app. The same 18+ rule, country limits, personal attributes rule and health claims rules apply wherever the ad is placed, so there is no looser Instagram route for GLP-1 ads.

**How do you get a weight loss ad approved on Facebook?**

Target people 18 and over, write the ad about the program instead of the viewer's body, keep pinched-fat close-ups and timed result promises without a disclaimer out of it, and send it to a landing page with none of those claims either. MedScale Health checks every GLP-1 ad and its landing page against Meta's health rules before it is submitted.

**Can a GLP-1 brand get a Meta ad account that is allowed to name the drug?**

Yes, once the brand is actively certified with LegitScript and Meta has authorized its ad account. Ads that promote the telehealth service generally, without the drug, need no authorization and can run before that. MedScale Health files the LegitScript application and the Meta authorization request, and if an account is already restricted, it starts with Ad Account Rescue.

## Sources

- [Meta Advertising Standards: Health and Wellness (updated Jul 22, 2026)](https://transparency.meta.com/policies/ad-standards/restricted-goods-services/health-wellness/) (checked November 3, 2026)
- [Meta Advertising Standards: Privacy Violations and Personal Attributes](https://transparency.meta.com/policies/ad-standards/objectionable-content/privacy-violations-personal-attributes/) (checked November 3, 2026)
- [Meta Advertising Standards: Drugs and Pharmaceuticals](https://transparency.meta.com/policies/ad-standards/restricted-goods-services/drugs-pharmaceuticals/) (checked November 3, 2026)
- [Meta Advertising Standards: Introduction](https://transparency.meta.com/policies/ad-standards/) (checked October 7, 2026)
- [Meta Business Help Center: About Meta's Prescription Drugs advertising policy](https://www.facebook.com/business/help/263390265553560) (checked October 7, 2026)
- [FDA (Jun 15, 2026): FDA to telehealth companies, what to know when promoting compounded drugs](https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs) (checked October 7, 2026)
- [FDA warning letter to a telehealth company, MARCS-CMS 737905 (Oct 30, 2026), compounded semaglutide and tirzepatide claims](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026) (checked November 9, 2026)

## Related

- [What Is Meta's Personal Attributes Policy and Why Does It Block Weight Loss Ads?](https://medscale.health/answers/meta-personal-attributes-policy-weight-loss)
- [Can You Use Before and After Photos in GLP-1 Ads?](https://medscale.health/answers/before-and-after-imagery-glp-1-ads)
- [GLP-1 Ad Examples That Pass Meta Review](https://medscale.health/answers/glp-1-ad-creative-that-survives-review)
- [Can You Advertise GLP-1 on Google Ads?](https://medscale.health/answers/google-ads-for-glp-1-telehealth)

Canonical page: https://medscale.health/answers/can-you-advertise-glp-1-on-meta